News

From our CEO

15 November 2022

It may have been Professor Sharon Friel who coined the phrase ‘No data, no problem, no action’.

It’s certainly a phrase I have been fond of using for some time. Because, when it comes to political decisions, especially in health care, if you don’t have data, you don’t get a look in.

With this political maxim at the back of my mind, I rolled up to a national workshop of neurological organisations earlier this year. I raised the issue of data gaps, and to my surprise, there was near universal agreement that data gaps were a major problem that confounded advocacy efforts. It’s certainly true for MS.

There was ready agreement that we needed to collectively push a ‘numbers matter’ campaign to secure a national minimum neurological data set.

And we have been doing exactly that. We have been engaged in discussions with the Australian Institute of Health and Welfare (AIHW) and the Federal Health Department, which, to their credit, readily acknowledge the national gap in neurological data.

It should be acknowledged that much of the data around prevalence and impact that does exist, is provided by the cash-strapped non-profit organisations at significant cost.

For most of the major disease groups, such as cancer, cardiovascular disease or diabetes, this data is collected through the AIHW at government expense.

It’s time – surely – that Australia comprehensively collects good data on neurological conditions – conditions that effect 1.6m Australians at a very significant cost to the health system.

Good data drives good resource allocation that, in turn, reduces costs for government.

So, our message to government is clear. Invest to save! A national minimum data set for neurological conditions should have been put in place years ago.

Time to do the right thing. Time to collect the data that matters.

Related News

MS News

Ocrevus and Kesimpta & the Government’s rapid review of MS medications

22 July 2026

On Thursday 16 July, the Australian Government announced that Ocrevus and Kesimpta would remain on the Pharmaceutical Benefits Scheme (PBS).

MS News

Thank you! Ocrevus and Kesimpta will remain on the PBS

17 July 2026

The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments. 

MS News

MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS

16 July 2026

MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).

Read More
ECTRIMS 2022John Studdy Award 2022

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

From our CEO